Literature DB >> 17067273

Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein.

Rong Xu1, Indresh K Srivastava, Catherine E Greer, Irina Zarkikh, Zane Kraft, Larene Kuller, John M Polo, Susan W Barnett, Leonidas Stamatatos.   

Abstract

In the present study, macaques were coimmunized with VEErep/SINenv chimeric alphavirus replicon particles expressing SIVp55Gag and HIVDeltaV2gp140Env or only with replicon particles expressing HIVDeltaV2gp140Env. All animals were subsequently immunized with recombinant trimeric HIVDeltaV2gp140Env protein. During alphavirus immunization, anti-SIVGag and anti-HIVEnv-specific interferon (IFN)-gamma responses, as well as high titers of anti-HIVEnv binding (gp120 but not gp41 specific) and anti-HIV neutralizing antibodies, were generated. The subsequent immunization with recombinant HIVDeltaV2gp140 enhanced the neutralizing antibody titers and Env-specific IFN-gamma responses. Following intravenous challenge with the R5- tropic SHIV(SF162P4) virus, significantly lower primary plasma viremia levels were recorded in the immunized animals, as compared to control animals immunized with replicon particles expressing influenza virus HA. Our results show that this method of immunization elicits both strong cellular immunity and neutralizing antibodies in primates and, thus, merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17067273     DOI: 10.1089/aid.2006.22.1022

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  18 in total

Review 1.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

2.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

3.  Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett
Journal:  Vaccine       Date:  2012-02-22       Impact factor: 3.641

4.  Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Authors:  Yasushi Uematsu; Michael Vajdy; Ying Lian; Silvia Perri; Catherine E Greer; Harold S Legg; Grazia Galli; Giulietta Saletti; Gillis R Otten; Rino Rappuoli; Susan W Barnett; John M Polo
Journal:  Clin Vaccine Immunol       Date:  2012-05-23

5.  Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Authors:  Susan W Barnett; Brian Burke; Yide Sun; Elaine Kan; Harold Legg; Ying Lian; Kristen Bost; Fengmin Zhou; Amanda Goodsell; Jan Zur Megede; John Polo; John Donnelly; Jeffrey Ulmer; Gillis R Otten; Christopher J Miller; Michael Vajdy; Indresh K Srivastava
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

6.  Viral vectors for vaccine applications.

Authors:  Youngjoo Choi; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

7.  The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.

Authors:  Lance K Ching; Giorgos Vlachogiannis; Katherine A Bosch; Leonidas Stamatatos
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

8.  Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody.

Authors:  Ilnour Ourmanov; Takeo Kuwata; Robert Goeken; Simoy Goldstein; Ranjani Iyengar; Alicia Buckler-White; Bernard Lafont; Vanessa M Hirsch
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

Review 9.  Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.

Authors:  Devon J Shedlock; Guido Silvestri; David B Weiner
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

10.  Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.

Authors:  Willy M J M Bogers; David Davis; Ilona Baak; Elaine Kan; Sam Hofman; Yide Sun; Daniella Mortier; Ying Lian; Herman Oostermeijer; Zahra Fagrouch; Rob Dubbes; Martin van der Maas; Petra Mooij; Gerrit Koopman; Ernst Verschoor; Johannes P M Langedijk; Jun Zhao; Egidio Brocca-Cofano; Marjorie Robert-Guroff; Indresh Srivastava; Susan Barnett; Jonathan L Heeney
Journal:  Virology       Date:  2008-10-22       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.